high quality TG 100801 from medchemexpress

TG 100801 is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD. The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible, severe loss of vision in people 55 years of age and older in the developed world. TG100801 is a new drug that inhibits ocular angiogenesis, vascular leak, and inflammation in laboratory studies, and may have great utility in the treatment of diseases such as AMD.
MedChemexpress (MCE) provides a wide range of research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs and Natural compounds for laboratory and scientific use. MCE has an enthusiastic, energetic and friendly Technical and Customer Support team with years of experience in the Life Science industry. MCE pay great attention on the purity, stability and activity of the compounds, esp. You can rely on us to be a competent and trustworthy partner.